Skip to main content

Affinity Asset Advisors, LLC

Position in VRDN — Viridian Therapeutics, Inc.\DE

CIK 1773195 NEW YORK, NY

Position in VRDN

as of Mar 31, 2026 · filed May 14, 2026
Position Value
$4,890,000
-$2,890,000 QoQ
Shares Held
250,000
0.0% QoQ
Ownership
0.243%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2022
13 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in VRDN Over Time

Shares Held

Position Value (USD)

Derivatives in VRDN

reported options exposure · as of Jun 30, 2023
CallValue
$3,102,216
CallShares
130,400
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

Affinity Asset Advisors, LLC holds $1,518,254,571 across 81 Biotechnology names. VRDN ranks #51 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in VRDN

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $4,890,000 250,000
2025-12-31 $7,780,000 250,000
2025-09-30 $5,395,000 250,000
2025-06-30 $5,452,200 390,000
2025-03-31 $5,257,200 390,000
2024-12-31 $3,059,800 159,614
2024-09-30 $11,943,750 525,000
2024-06-30 $1,951,500 150,000
2023-12-31 $1,089,000 50,000
2023-06-30 $3,102,216 130,400
2023-03-31 $2,556,720 100,500
2022-06-30 $239,036 20,660
2022-03-31 $924,500 50,000